NexMed Announces The Expansion Of Its Senior Management Team
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT ® technology, announced today announced the expansion of its senior management team within its operating subsidiaries, with the appointment of Terry Ladd as Vice-President of Business Development at Bio-Quant, Inc. and Richard Martin, Ph.D., as Vice President of Chemistry for NexMed (U.S.A.), Inc. Both executives will report to Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, Inc.
In his new position, effective April 12, 2010, Mr. Ladd will be responsible for the worldwide business development operations of Bio-Quant, NexMed’s discovery pre-clinical service subsidiary. Mr. Ladd brings more than 20 years of sales experience in the preclinical field, including senior management positions in sales and marketing with Calvert Laboratories, Inc., MDS Pharma Services, Inc., SkeleTech, Inc., Phoenix International Life Sciences, Inc., Chrysalis International, Inc., Pharmakon Research International, Inc., and ITR Laboratories, Inc. Mr. Ladd holds an M.B.A. in Marketing and Finance from McGill University, an M.A. from the University of Sherbrooke, and a B.A. Honors degree from Bishop’s University.
As Vice President of Chemistry, effective immediately, Dr. Martin is leading the development work for the next generation of NexACT technology and NexACT-based products at NexMed (U.S.A.). Dr. Martin has over 20 years of medicinal chemistry research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, cardiovascular and metabolic diseases. Prior to joining NexMed (U.S.A.), Dr. Martin was Senior Director of Chemistry at RetroVirox, Inc. a privately-held biotechnology company engaged in the discovery of new treatments for patients with infectious diseases. Dr. Martin also served as Director of Chemistry at Exelixis, Inc./X-Ceptor Therapeutics, Inc. and Group Leader at Tanabe Research Laboratories U.S.A., Inc. in San Diego -- a wholly owned subsidiary of Mitsubishi-Tanabe in Japan. Dr. Martin received his Ph.D. in Organic Chemistry from the University of Toronto and completed his postdoctoral research at The Scripps Research Institute in San Diego. Dr. Martin holds over 20 patents and patent applications and has authored/co-authored over 20 papers.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV